Needham Initiates Coverage On Praxis Precision Medicine with Buy Rating, Announces Price Target of $145
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Buy rating and sets a price target of $145.
June 24, 2024 | 9:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia has initiated coverage on Praxis Precision Medicine with a Buy rating and a price target of $145.
The initiation of coverage with a Buy rating and a high price target of $145 by a reputable analyst is likely to positively impact the stock price of Praxis Precision Medicine in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100